FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

BMS inks $227M collaboration deal with KAI

South San Francisco-based KAI Pharmaceuticals is getting a $25 million boost from Bristol-Myers Squibb---its upfront payment for a collaboration on KAI-9803, an experimental therapy to reduce the severity of a heart attack and improve clinical outcomes. BMS will also buy $10 million in KAI equity and up to $192 million in milestone payments and will pay for all future development efforts, including an upcoming Phase IIb. KAI also retains co-promotion rights in the U.S.

"This is a major milestone for KAI-9803, our most advanced of three clinical programs, and a strategically important collaboration for KAI," says CEO Steven James. "Bristol-Myers Squibb is a great partner for us with its impressive history of developing and commercializing breakthrough medicines in cardiovascular disease. We believe this deal is testimony to the value and potential of KAI-9803 and our broad proprietary technology around protein kinase C modulation." KAI was a 2006 Fierce 15 company.

- check out the press release
- read the Dow Jones report

Related Articles:
BMS: Buyer or buyout target?
Bristol profits leap on Plavix sales
BMS cuts 4,800 jobs

More stories about milestones   Deals   heart disease   KAI-9803   KAI Pharmaceuticals   Bristol-Myers Squibb   Phase II   experimental therapy   upfront payment   Plavix  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 28 + 53?
To combat spam, please solve the math question above.